Bimekizumab Efficacy and Safety Through 2 years in Patients with Hidradenitis Suppurativa: Results from the Phase 3 BE HEARD I&II trials and Open-Label Extension BE HEARD EXT. (2024). SKIN The Journal of Cutaneous Medicine, 8(6), s473. https://doi.org/10.25251/skin.8.supp.473